Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain

• Main Authors: Enrique Casado (Author), Jose Rosas (Author), Carlos Rubio-Terres (Author), Dario Rubio-Rodriguez (Author), Mitra Boolell (Author), Ignacio Aristegui (Author)
• Format: Book
• Published: Becaris Publishing Limited, 2023-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Aim: To estimate the cost-effectiveness of treating postmenopausal osteoporosis (PMO) with weekly gastro-resistant risedronate 35 mg gastro-resistant tablets (RIS-GR), compared with weekly alendronate 70 mg tablets (ALN) in Spain. Methods: A probabilistic analysis (second-orderMonte Carlo simulation...